# The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen

> **NCT06362720** · — · UNKNOWN · sponsor: **Siriraj Hospital** · enrollment: 158 (estimated)

## Conditions studied

- CMV Infection or Reactivation After Allogenic HSCT

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06362720
- **Lead sponsor:** Siriraj Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05-01
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06362720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06362720, "The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06362720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*